Effects of molsidomine and lexipafant in hepatic ischaemia-reperfusion injury

Basit Öğe Kaydı
dc.contributor.authorAldemir, M
dc.contributor.authorBoşnak, Mehmet
dc.contributor.authorAl, B
dc.contributor.authorBüyükbayram, H
dc.contributor.authorTaçyildiz, I
dc.date.accessioned2024-04-24T16:18:39Z
dc.date.available2024-04-24T16:18:39Z
dc.date.issued2004
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: The purpose of this study was to evaluate the effects of nitric oxide donor molsidomine and platelet-activating factor (PAF) antagonist lexipafant on the hepatic IR injury in rats. Methods: Fifty mate Sprague-Dawley rats (200-225 g) were divided into five groups each containing 10 rats; group SO: Sham operation group; group 1: hepatic ischaemia group; group IR: ischaernia-reperfusion (IR); group M: IR plus pretreatment with molsidomine; group L: IR plus pretreatment with lexipafant. Hepatic ischaemia and reperfusion, each were applied for 45 min. Hepatic specimens were obtained to determine the tissue levels of malondialdehyde (MDA) and histological changes. Blood samples were obtained by cardiac puncture for determination of alanine transaminase (ALT), aspartate transaminase (AST) and lactic dehydrogenase (LDH). Results: The liver damage scores of groups 1, IR, M and L were significantly higher than that of group SO (P < 0.001). The liver damage scores of groups IR and M, were significantly higher than that of group 1 (P = 0.009 and 0.0035, respectively). The liver damage scores of groups M and L were significantly tower than that of group IR (P < 0.001 for both M and L). Mean MDA levels of groups 1 and IR were significantly higher than those of group SO (P < 0.001). Administrations of molsidomine and lexipafant prior to ischaernia-reperfusion (IR) resulted in significant reduction of the MDA values (P < 0.001). A statistically significant (P < 0.001) decrease in the levels of AST, ALT and LDH was observed in groups M and L compared with group IR. Conclusion: In conclusion, these observations suggest that pre-treatment with nitric oxide donor molsidomine and PAF antagonist lexipafant before the reperfusion period may be useful in preventing hepatic reperfusion injury. ((C))2003 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/S0020-1383(03)00217-1
dc.identifier.endpage237en_US
dc.identifier.issn0020-1383
dc.identifier.issue3en_US
dc.identifier.pmid15124788
dc.identifier.scopus2-s2.0-1242270580
dc.identifier.scopusqualityQ1
dc.identifier.startpage232en_US
dc.identifier.urihttps://doi.org/10.1016/S0020-1383(03)00217-1
dc.identifier.urihttps://hdl.handle.net/11468/16218
dc.identifier.volume35en_US
dc.identifier.wosWOS:000189229400004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofInjury-International Journal of The Care of The Injured
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnimalen_US
dc.subjectLexipafanten_US
dc.subjectLiveren_US
dc.subjectScoreen_US
dc.subjectIschaemia-Reperfusionen_US
dc.subjectMolsidomineen_US
dc.subjectMaleen_US
dc.subjectMalondialdehydeen_US
dc.subjectMicroscopyen_US
dc.subjectPringle Manoeuvreen_US
dc.subjectSprague-Dawley Ratsen_US
dc.subjectTherapyen_US
dc.titleEffects of molsidomine and lexipafant in hepatic ischaemia-reperfusion injuryen_US
dc.titleEffects of molsidomine and lexipafant in hepatic ischaemia-reperfusion injury
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu